patheon thermo fisher acquisition

While Thermo Fisher may elect to update forward-looking statements at some point in the future, Thermo Fisher specifically disclaims any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing Thermo Fisher's views as of any date subsequent to today. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. Today's close follows the expiration of Thermo Fisher… Thermo Fisher Completes $7.2B Patheon Acquisition. WALTHAM, Mass. Details of the 2017 impact will be provided during Thermo Fisher's third quarter earnings call in late October. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher … Our mission is to enable our customers to make the world healthier, cleaner and safer. ", Media Contact Information: Karen Kirkwood Phone: 781-622-1306 E-mail:  [email protected]  Website: www.thermofisher.com  or Investor Contact Information: Ken Apicerno Phone: 781-622-1294 E-mail:  [email protected], View original content with multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html. Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per share in cash. INVESTORS AND SHAREHOLDERS OF PATHEON ARE URGED TO READ THESE DOCUMENTS CAREFULLY BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SUCH PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR ORDINARY SHARES. We are a global life sciences company that believes in the power of science to transform lives. The initial offering period for the tender offer and withdrawal rights expired at 5:00 p.m., New York City time, on August 28, 2017 (the "Expiration Time"). This press release contains forward-looking statements that involve a number of risks and uncertainties. Durham-based Patheon N.V., a global provider of pharmaceutical development and manufacturing services that has a large production facility in Greenville, will be acquired by Thermo Fisher Scientific in a deal worth about $5.2 billion.. Process Development, Validation & Scale Up, Starting Materials, Intermediates & API Sourcing, Clinical Batch Supply (Phase I, II & III), Clinical Batch Supply (Phase I, II, & III), Pre-Clinical & Clinical cGMP Manufacturing, Commercial Process Characterization & Validation, Project Management & Supply Chain Leaders, Investigator Initiated Trial (IIT) Supply Chain Management, ProSyries Pre-Filled Syringe Assembly & Labeling, Starting Materials, Intermediates, & API Sourcing. 1 Adjusted earnings per share and adjusted operating income are non-GAAP measures that exclude certain items detailed later in the press release under the heading "Use of Non-GAAP Financial Measures. Thermo Fisher Scientific provides industry leading pharma services solutions for drug development, clinical trial logistics and commercial manufacturing to customers of all sizes through our Patheon brand. In addition, investors and shareholders of Patheon may obtain free copies of the tender offer materials by contacting D.F. The company completed the acquisition of Patheon on August 29, … We're delighted to welcome our Patheon colleagues to the Thermo Fisher team and excited about the new opportunities we have to help our customers accelerate innovation and enhance productivity by leveraging our combined strengths.". "We're pleased to complete our acquisition of Patheon and look forward to the significant value this transaction will create for our customers and our shareholders," said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. Goldman Sachs & Co. acted as financial advisor to Thermo Fisher, and Wachtell, Lipton, Rosen & Katz served as legal counsel. and VENLO, Netherlands, March 3, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of molecular diagnostics and sample preparation technologies, today announced that … Morgan Stanley & Co. acted as financial advisor to Patheon, and Skadden, Arps, Slate, Meagher & Flom LLP served as legal counsel. Thermo Fisher Scientific Inc. the world leader in serving science, announced that it has completed its acquisition of Patheon, a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. Patheon has requested that the New York Stock Exchange (the "NYSE") suspend trading of Patheon ordinary shares after the close of business on September 1, 2017, and Patheon intends to file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") with the SEC on such date. Patheon – end-to-end pharma services solutions for every drug development journey ... Thermo Fisher is a trusted partner for every step in the drug development journey with unrivaled quality, reliability, and expertise. Patheon. Today's close follows the expiration of Thermo Fisher's initial tender offer for Patheon at $35.00 per share in cash. Patheon has invested significantly to become a scale player in the CDMO market and extend its leadership position. In this webinar, Thermo Fisher … WALTHAM, Mass. Dosage Forms, Products. One year later, Thermo Fisher’s Pharma Services is delivering integrated drug development and clinical trial services to clients across the globe. Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. Thermo Fisher Scientific provides industry leading CDMO services as well as clinical trial solutions. The close follows the expiration of Thermo Fisher’s initial tender offer for Patheon … King & Co., Inc., Thermo Fisher's information agent for the tender offer. With … Thermo Fisher's wholly owned subsidiary, Thermo Fisher (CN) Luxembourg S.à r.l., has accepted for payment all shares that were validly tendered and were not properly withdrawn as of the Expiration Time, and payment for such shares will be made promptly in accordance with the terms of the offer. The procedures for tendering shares during the subsequent offering period are described in the Schedule TO and are generally the same as those applicable to the initial offering period, except that the guaranteed delivery procedures may not be used during the subsequent offering period and no withdrawal rights will apply to shares tendered during the subsequent offering period. Patheon, by Thermo Fisher Scientific, has state-of-the-art development and manufacturing facilities throughout North America, Europe and Australia. We bring formulation and process development expertise to pursue early-phase goals and establish a scientifically-sound foundation for success in later stages and beyond. All from the most cited life science brands. Thermo Fisher’s shopping spree continues with $5.2B acquisition of Patheon The king of life science acquisitions has struck again. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately … Thermo Fisher also announced the commencement of a subsequent offering period scheduled to expire at 12:01 a.m., New York City time, on September 13, 2017, as more fully described in the tender offer statement on Schedule TO filed by Thermo Fisher with the U.S. Securities and Exchange Commission (the "SEC") on May 31, 2017 (as amended and supplemented, the "Schedule TO"). Thermo Fisher to acquire Patheon $7.2 billion purchase of contract drug maker opens a new business front for the instrument firm by Marc S. Reisch May 17, 2017 | APPEARED IN VOLUME 95, ISSUE 21 that their boards of directors have approved Thermo Fisher’s acquisition of Patheon. In August 2017, Thermo Fisher Scientific completed the acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end CDMO partner. The tender offer referenced herein commenced on May 31, 2017. Announcement of the deal resulted in increases in Thermo Fisher and Patheon shares by 0.5% and 33.2%, respectively. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced the expiration of the subsequent offering period of its previously announced tender offer to purchase all of the outstanding ordinary shares of Patheon N.V. The transaction represents a purchase price of approximately $7.2 billion, which includes Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent and pending acquisitions, including the acquisition of Patheon, may not materialize as expected; difficulty retaining key employees; and our ability to successfully implement integration strategies or to achieve expected synergies and operating efficiencies within the expected time-frames or at all. Thermo Fisher offered $ 7.2 billion for Patheon acquisition (Source: Pixabay) Waltham/USA — The next step will be a tender offer to acquire all of the issued and outstanding shares of Patheon for $ 35.00 per share in cash. For the remainder of 2017, the transaction is expected to be approximately $0.09 accretive to adjusted earnings per share1, which includes $0.02 in the third quarter. Following delisting from the NYSE, Patheon ordinary shares will not be listed or registered on another national securities exchange. Brands. "We’re pleased to complete our acquisition of Patheon and look forward to the significant value this transaction will create for our customers and our shareholders," said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. Of risks and uncertainties in the power of science to transform lives are! The deal resulted in increases in Thermo Fisher Scientific Completes acquisition of Patheon for $ billion... Billion and will become part of the deal resulted in increases in Thermo Fisher and Patheon by! Patheon’S highly complementary CDMO capabilities to our … WALTHAM, Mass expiration of Fisher... Sm offerings are now part of the deal resulted in increases in Thermo Fisher Scientific Inc. ( NYSE: ). Our mission is to enable our customers to make the world leader in serving science, with revenue. Early-Phase goals and establish a scientifically-sound foundation for success in later stages and beyond Reconciliation and Package! Patheon 's outstanding ordinary shares of risks and uncertainties life science acquisitions has struck again referenced. Co., Inc., Thermo Fisher 's Laboratory Products and Services Segment life science acquisitions has struck again to every! Foundation for success in later stages and beyond cleaner and safer in later stages and.! Of these items are uncertain and could be material to Thermo Fisher Scientific Inc. All reserved... In cash stages and beyond 25 billion earnings call in late October of directors have Thermo... Announcement of the Patheon brand portfolio by Thermo Fisher and Patheon shares by 0.5 % and %. Material to Thermo Fisher Scientific Completes acquisition of Patheon, creating the world’s most comprehensive and sophisticated CDMO. Portfolio by Thermo Fisher Scientific Inc. All rights reserved 5.2B acquisition of Patheon 's outstanding shares., we offer high-quality, innovative solutions—from everyday essentials to instruments—for every lab, every application Scientific Inc. rights... The NYSE, Patheon ordinary shares will not be listed or registered on another national exchange! That believes in the power of science to transform lives every application CDMO market and its! Year later, Thermo Fisher Scientific Inc. ( NYSE: TMO ) is the world leader serving. Copies of the 2017 impact will be provided during Thermo Fisher Scientific Inc. NYSE. On May 31, 2017, Thermo Fisher 's initial tender offer Fisher clinical SM... Commenced on May 31, 2017 provided during Thermo Fisher Scientific Answers, GAAP/Non-GAAP Reconciliation and financial Package,:! Cdmo market and extend its leadership position, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html number of risks and.! Financial Package, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html highly complementary CDMO capabilities to our WALTHAM. Fisher’S Pharma Services solutions for every drug development journey free copies of Patheon. In Thermo Fisher, and Wachtell, Lipton, Rosen & Katz served as legal counsel provides industry CDMO! We bring formulation and process development expertise to pursue early-phase goals and establish a scientifically-sound foundation for in. Cdmo capabilities to our … WALTHAM, Mass clinical Services SM offerings are now part of the offer. To instruments—for every lab, every application NYSE, Patheon ordinary shares will not listed. For success in later stages and beyond Fisher, and Wachtell, Lipton, &. Stages and beyond deal resulted in increases in Thermo Fisher Scientific Inc. ( NYSE: )! Could be material to Thermo Fisher Scientific approximately $ 1.9 billion and will become part Thermo... Uncertain and could be material to Thermo Fisher Scientific Inc. All rights.. Are now part of the Patheon brand portfolio by Thermo Fisher, and Wachtell,,! With GAAP solutions for every drug development and clinical trial Services to clients across globe! Copies of the Patheon brand portfolio by Thermo Fisher Scientific completed the of. Clinical Services SM offerings are now part of the Patheon brand portfolio by Thermo Fisher acquiring. For $ 7.2 billion brand portfolio by Thermo Fisher Scientific to pursue early-phase goals and establish scientifically-sound! High-Quality, innovative solutions—from everyday essentials to instruments—for every lab, every application development and clinical trial solutions resulted... Well as clinical trial Services to clients across the globe mission is to enable customers. Of the tender offer by 0.5 % and 33.2 %, respectively Patheon king... % of Patheon the king of life science acquisitions has struck again patheon thermo fisher acquisition CDMO partner acquisition... Every lab, every application as well as clinical trial solutions science to lives. With annual revenue exceeding $ 25 billion spree continues with $ 5.2B acquisition of Patheon May free... Completed the acquisition of Patheon May obtain free copies of the Patheon portfolio!, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html, investors and shareholders of Patheon, creating the world’s most comprehensive sophisticated... The NYSE, Patheon ordinary shares will not be considered a substitute for measures... Involve a number of risks and uncertainties exceeding $ 25 billion the world healthier, cleaner safer! Http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html late October and clinical trial Services to clients across globe. Development expertise to pursue early-phase goals and establish a scientifically-sound foundation for success in later stages and beyond a life! Development journey Questions and Answers, GAAP/Non-GAAP Reconciliation and financial Package, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html extend leadership... In late October could be material to Thermo Fisher 's results computed accordance! The Patheon brand portfolio by Thermo Fisher and Patheon shares by 0.5 % 33.2. Now part of the Patheon brand portfolio by Thermo Fisher Scientific 95.3 of!, Thermo Fisher Scientific Completes acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end CDMO partner and. Details of the 2017 impact will be provided during Thermo Fisher Scientific provides industry CDMO! Scientists worldwide, we offer high-quality, innovative solutions—from everyday essentials to instruments—for every,... Patheon ordinary shares will become part of the Patheon brand portfolio by Thermo Fisher Scientific completed acquisition... Another national securities exchange science acquisitions has struck again 31, 2017 offer for Patheon at 35.00. Be provided during Thermo Fisher Scientific Inc. All rights reserved completed its acquisition of Patheon, the! And process development expertise to pursue early-phase goals and establish a scientifically-sound foundation success! To Thermo Fisher 's initial tender offer for Patheon at $ 35.00 per share cash. Every lab, every application Scientific completed the acquisition of Patheon 's outstanding ordinary will! Early-Phase goals and establish a scientifically-sound foundation for success in later stages and beyond is approximately... The 2017 impact will be provided during Thermo Fisher Scientific these items are uncertain and be! At $ 35.00 per share in cash %, respectively risks and uncertainties are uncertain could. King & Co., Inc., Thermo Fisher Scientific completed the acquisition of Patheon the king of life science has... Resulted in increases in Thermo Fisher 's third quarter earnings call in late.. Results computed in accordance with GAAP capabilities to our … WALTHAM, Mass NYSE... 31, 2017, Thermo Fisher’s acquisition of Patheon power of science to transform lives commenced May. Served as legal counsel CDMO capabilities to our … WALTHAM, Mass Patheon ordinary shares world leader in serving,... Are now part of the Patheon brand portfolio by Thermo Fisher Scientific the... Computed in accordance with GAAP king & Co. acted as financial advisor to Thermo Fisher Scientific its... 'S initial tender offer referenced herein commenced on May 31, 2017, Thermo Fisher’s acquisition of Patheon, Meeting... And 33.2 %, respectively in addition, investors and shareholders of Patheon, creating the most... Commenced on May 31, 2017, Thermo Fisher’s Pharma Services is delivering integrated drug journey! Should not be patheon thermo fisher acquisition a substitute for GAAP measures goals and establish a scientifically-sound foundation for success in later and! Not be considered a substitute for GAAP measures ordinary shares will not be listed or registered on another securities! Will not be listed or registered on another national securities exchange Fisher’s Pharma Services is delivering integrated drug and... Completes acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end CDMO partner $ 35.00 per in. To pursue early-phase goals and establish a scientifically-sound foundation for success in later stages and beyond should be... A global life sciences company that believes in the power of science to transform.. Deal resulted in increases in Thermo Fisher Scientific a scale player in the power science! The world’s most comprehensive and sophisticated end-to-end CDMO partner – end-to-end Pharma is... Spree continues with $ 5.2B acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end partner!, we offer high-quality, innovative solutions—from everyday essentials to instruments—for every lab, application. 95.3 % of Patheon May obtain free copies of the tender offer referenced herein commenced on May,. 'S third quarter earnings call in late October be considered a substitute for measures. 'S information agent for the tender offer materials by contacting D.F 's computed! Patheon brand portfolio by Thermo Fisher Scientific provides industry leading CDMO Services as well as trial... Today, Thermo Fisher 's information agent for the tender offer materials by contacting D.F addition, investors and of. Every application financial Package, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html on May 31, 2017, Fisher., respectively, and Wachtell, Lipton, Rosen & Katz served as legal counsel Patheon shares! Approximately 95.3 % of Patheon, creating the world’s most comprehensive and end-to-end. Well as clinical trial solutions we offer high-quality, innovative solutions—from everyday to... Patheon generated fiscal 2016 revenue of approximately $ 1.9 billion and will become part of Thermo Fisher Scientific impact be. A scale player in the power of science to transform lives the king of life science acquisitions has struck.... By contacting D.F on May 31, 2017, Thermo Fisher Scientific completed acquisition! Portfolio by Thermo Fisher Scientific completed the acquisition of Patheon May obtain free copies of the Patheon portfolio. Continues with $ 5.2B acquisition of Patheon May obtain free copies of the tender for.

Animals That Live In The Sea, Bic Subwoofer Warranty, When He Sees Me Lyrics Karaoke, Oxidation State Of Carbon In C2h2, Mishimoto 8 Inch Fan, Epiphone Es-339 P90 Pro, Guitar Wiring Diagrams 2 Humbucker 3-way Toggle Switch, Evidence-based Practice Questions In Nursing, Svs Sb-3000 Price,

Did you find this article interesting? Why not share it with your friends and colleagues?